MHRA has authorized use of Oxford/AstraZeneca vaccine

MHRA has authorized use of Oxford/AstraZeneca vaccine, goal to “give as many people in at-risk groups their first dose” but recommending a 2nd up to 3 months later.

Safety information from the trials:

The most frequently reported adverse reactions were injection site tenderness (>60%); injection site pain, headache, fatigue (>50%); myalgia, malaise (>40%); pyrexia, chills (>30%); and arthralgia, nausea (>20%). The majority of adverse reactions were mild to moderate in severity and usually resolved within a few days of vaccination. By day 7 the incidence of subjects with at least one local or systemic reaction was 4% and 13% respectively. When compared with the first dose, adverse reactions reported after the second dose were milder and reported less frequently.
Adverse reactions were generally milder and reported less frequently in older adults (≥65 years old).